Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?

World Journal of Gastroenterology

Volumn 21, Issue 29, 2015, Pages 8787-8803

  Suzuki, Eiichiro ^a   Chiba, Tetsuhiro ^a   Ooka, Yoshihiko ^a   Ogasawara, Sadahisa ^a   Tawada, Akinobu ^a   Motoyama, Tenyu ^a   Kanogawa, Naoya ^a   Saito, Tomoko ^a   Yoshikawa, Masaharu ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Interventional radiology; Prognostic factor; Survival; Transcatheter arterial infusion

Indexed keywords

BILIRUBIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LACTATE DEHYDROGENASE; MIRIPLATIN; PIRARUBICIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVOR; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TRANSCATHETER ARTERIAL INFUSION CHEMOTHERAPY; TREATMENT RESPONSE; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT SYSTEM; INTRAARTERIAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939817821     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i29.8888     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855]
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269]
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/ hep.20933]
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666]
5. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48: 599-641 [PMID: 22424278]
6. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364 [PMID: 21829027]
7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474 [PMID: 20827404]
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 [PMID: 12540794]
9. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54 [PMID: 12091661]
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514]
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497]
12. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014; 87: 330-341 [PMID: 25227534]
13. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-693 [PMID: 2961314]
14. Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer 1981; 47: 402-409 [PMID: 6257376]
15. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2009; 51: 1030-1036 [PMID: 19864035]
16. Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, Sasaki Y. Transcatheter arterial infusion chemotherapy with cisplatinlipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 2010; 45: 60-67 [PMID: 19655081]
17. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, Yokoyama Y, Takami T, Omori K, Kawaguchi K, Tsuchiya M, Terai S, Sakaida I, Okita K. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-78 [PMID: 15692792]
18. Okimoto K, Ogasawara S, Chiba T, Ooka Y, Oobu M, Azemoto R, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yoshikawa M, Yokosuka O. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. Anticancer Res 2013; 33: 5603-5609 [PMID: 24324105]
19. Tawada A, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Ogasawara S, Suzuki E, Kanai F, Yoshikawa M, Yokosuka O. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. Anticancer Res 2015; 35: 549-554 [PMID: 25550601]
20. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40: 686-692 [PMID: 20633194]
21. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 [PMID: 11981766]
22. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-220 [PMID: 20724077]
23. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-1335 [PMID: 22314428]
24. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol 2012; 35: 1119-1128 [PMID: 22614031]
25. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T. A phase II study of uraciltegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 2009; 65: 113-120 [PMID: 19404641]
26. Chen J, Sun MX, Hua YQ, Cai ZD. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a metaanalysis. J Cancer Res Clin Oncol 2014; 140: 1205-1210 [PMID: 24682390]
27. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010; 79: 39-45 [PMID: 21063134]
28. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 2007; 37: 114-120 [PMID: 17272317]
29. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469 [PMID: 16890600]
30. Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol 2013; 24: 490-500 [PMID: 23466316]